Mankind Pharma Navigates Domestic Headwinds And GST Disruptions, Margin Guidance Remains Firm

Mankind Pharma, India’s fourth-largest drugmaker by domestic sales, reported a mixed performance in Q2 FY26, impacted by macroeconomic headwinds and operational transitions. The company’s net profit declined 21.3% year-on-year to ₹520 crore, weighed down by higher finance costs and depreciation linked to the BSV acquisition. Revenue, however, rose 20.8% to ₹3,697 crore, supported by strong export momentum and chronic therapy growth.

The company attributed the slowdown to uneven monsoons, GST 2.0 implementation challenges, and slower-than-expected synergy realization from BSV. Despite these pressures, Mankind reaffirmed its EBITDA margin guidance of 25–26%, citing confidence in its long-term growth strategy.

Key highlights from the quarterly update include:  

• Domestic revenue grew 18.9% YoY to ₹3,101 crore, though OTC sales declined due to monsoon disruptions and GST transition.
• Export business surged 83% YoY to ₹513 crore, driven by expanding global reach and product portfolio.
• BSV integration remains in progress, with double-digit sequential growth in mandate brands, though synergy realization is slower than anticipated.
• Finance costs spiked to ₹169.68 crore in Q2 FY26, up from ₹7.10 crore in Q2 FY25, reflecting acquisition-linked debt servicing.
• Chronic therapies outperformed the Indian Pharmaceutical Market (IPM), with cardiac and antidiabetic segments growing 1.2x and 1.3x faster, respectively.
• EBITDA rose 8.8% to ₹921.8 crore, though margins contracted to 24.9% from 27.7% a year earlier.
• Management remains optimistic about H2 recovery, driven by base business stability, specialty chronic expansion, and OTC rebound.
• Mankind’s leadership emphasized continued investment in R&D, digital transformation, and workforce optimization to sustain long-term growth.

Sources: Moneycontrol, Business Standard, Medical Dialogues, CNBC TV18, ScanX News.